Total company revenue fell from a peak of $19.3 billion in 2022 to $3.2 billion for the full year ended Dec. 31, 2024. For ...

Moderna (NASDAQ:MRNA) shares jumped 16% on Wednesday, March 5, following a favorable German court decision that determined BioNTech and Pfizer violated Moderna’s ...

Shares of vaccine-maker Moderna MRNA closed at $34.71 on Monday, close to their 52-week low of $29.25. Moderna is facing several headwinds, including the declining COVID-19 vaccine and the soft sales ...

two purchases of Moderna's stock by a firm controlled by MRNA CEO Stephane Bancel were reported. Bancel's company, called Boston Biotech Ventures, bought 102,821 shares for an average price of $31.04.

Shares of the American pharmaceutical company Moderna (MRNA) climbed over 8% in pre-market trading following strategic ...

Is MRNA stock a sell? Investing.com -- Citi has ... Moderna has gotten torched over the last six months - since September 2024, its stock price has dropped 51.2% to $33.99 per share.

Wealthfront Advisers LLC lowered its stake in shares of Moderna, Inc. (NASDAQ:MRNA – Free Report) by 84.4% during the fourth quarter, according to the company in its most recent disclosure with the ...

If an investor was to purchase shares of MRNA stock at the current price level of $35.87/share, and then sell-to-open that call contract as a "covered call," they are committing to sell the stock ...

1 Day MRNA 0.93% DJIA 1.65% S&P 500 2.13% Health Care/Life Sciences -0.59% The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing ...